Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 4, Issue 5, 2022

To Explore the Mechanism of Jinshui Tinling Decoction in the Treatment of Malignant Pleural Effusion Based on Network Pharmacology and Molecular Docking Technology

Download as PDF

DOI: 10.23977/medcm.2022.040502 | Downloads: 57 | Views: 1077

Author(s)

Baogang Yang 1, Chenguang Yang 2, Jiao Gou 2

Affiliation(s)

1 Shaanxi University of Traditional Chinese Medicine, Xianyang, 712046, China
2 Shaanxi Hospital of Traditional Chinese Medicine, Xi'an, 710000, China

Corresponding Author

Chenguang Yang

ABSTRACT

Objective To explore the mechanism of action of Jingshui Tinling decoction (JSTLD) treating Malignant pleural effusion (MPE) by using network pharmacology and molecular docking technology. Methods The active components of JSTLD were screened by TCMSP database and UniProt database. The targets related to MPE were screened by Genecards database and OMIM database, and the intersection targets of active components and disease-related targets were obtained, namely, the targets of JSTLD in the treatment of MPE. Cytoscape 3.8.2 software was used to construct the "drug-active ingredient-target" network, and the core active components in the network were analyzed. The intersection targets were imported into STRING database for protein interaction (PPI) network analysis, and core targets were screened out. GO and KEGG enrichment analysis of core targets were carried out. Autodock vina 1.1.2 software was used for molecular docking of core components and targets. Results Network pharmacological prediction showed that there were 153 active components of JSTLD, 8463 corresponding target genes, 1539 MPE disease-related targets, and 106 intersection targets. The core active components such as quercetin, β-sitosterol, kaempferol and stigmasterol were obtained. AKT1, TP53, IL1B, CASP3, JUN, EGFR and other core targets; A total of 233 signaling pathways were screened, and the key pathways included cancer pathways. The molecular docking results are good. Conclusion JSTLD may act on AKT1, TP53, IL1B, CASP3, JUN, EGFR and other targets, and inhibit MPE through the cancer pathway and other related pathways.

KEYWORDS

Malignant pleural effusion, jingshui Tinling decoction, network pharmacology, β-sitosterol, AKT1, molecular docking

CITE THIS PAPER

Baogang Yang, Chenguang Yang, Jiao Gou, To Explore the Mechanism of Jinshui Tinling Decoction in the Treatment of Malignant Pleural Effusion Based on Network Pharmacology and Molecular Docking Technology. MEDS Chinese Medicine (2022) Vol. 4: 11-23. DOI: http://dx.doi.org/10.23977/medcm.2022.040502.

REFERENCES

[1] Fitzgerald Db, Koegelenberg C, Yasufuku K, Et al. Surgical and non-surgical management of malignant pleural effusions [J]. Expert Rev Respir Med, 2018, 12(1): 15 to 26. 
[2] Feller-Kopman DJ, Reddy CB, DeCamp MM, et al. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198 (7): 839-849. 
[3] Bibby AC, Dorn P, Psallidas I, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J. 2018; 52(1): 1800349. Published 2018 Jul 27. 
[4] Recuero Diaz JL, Figueroa Almanzar S, Galvez Munoz C, et al. Recommendations of the Spanish Society of Thoracic Surgery for the management of malignant pleural effusion. Cir Esp (Engl Ed). 2022 Jun 3: S2173-5077(22)00160-0.
[5] Yang Chenguang, Wang Songhai, Xu Peng. Treatment of malignant pleural effusion from the perspective of water and fire in mingmen [J]. Shaanxi journal of traditional Chinese medicine, 2019, 40(2): 247-249. 
[6] Yang C G. A kind of Chinese medicine composition used in the treatment of malignant pleural effusion [P]. China Invention Patent, CN111939239B. 2022-02-01. 
[7] Kang Chao, Yang Baogang, Yang Chenguang, et al. A retrospective analysis of Mingmen theory in the treatment of malignant pleural effusion [J]. Clinical Medical Research & Practice. 2022(13): 94-97. 
[8] Yu Q, Fan L, Duan Z. Five individual polyphenols as tyrosi⁃ nase inhibitors: inhibitory activity, synergistic effect, action mechanism and molecular docking [J]. Food Chem, 2019, 297: 124910. 
[9] Salaverry L S, Parrado A C, Mangone F M, et al. In vitro anti-inflammatory properties of Smilax campestris desalination extract in human macrophages. characterization of full its flavo⁃ noid profile [J]. J Ethnopharmacol, 2020, 247: 112-282. 
[10] Shathviha PC, Ezhilarasan D, Rajeshkumar S, et al. β-sitosterol mediated silver nanoparticles induce cyto⁃ toxicity in human colon cancer HT-29 cells [J]. Avi⁃ cenna J Med Biotechnol, 2021,13 (1): 42-46. 
[11] Luna-Herrera C, Intranigral administration of β-sitosterol-β-D-glucoside elicits neurotoxic A1, MARTINEZ DAVILA LA, SOTOROJASLO, et al. Intranigral administration of β-Sitosterol-β-D-glucoside Elicits Neurotoxic A1 astrocyte reactivity and chronic neuroinflammation in the rat substantia nigra [J]. J Immunol Res, 2020 (712): 1-19. 
[12] Chen Y ,  Chen J ,  Sun K , et al. To Explore the Mechanism of Dahuang Fuzi Xixin Decoction in Treatment of Renal Interstitial Fibrosis Based on Network Pharmacology[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2020. 
[13] Wang H J, Chen L Y, Zhang X Y, Et Al. Kaempferol protects mice from d-GalN/LPS-induced acute liver failure by regulating the ER stress-Grp78-CHOP signaling pathway [J]. Biomed Pharmacoth, 2019, 111(12): 468-475. 
[14] Han X, Liu C F, Gao N, et al. Kaempferol suppresses proliferation but increases apoptosis and autophagy by up-regulating microRNA-340 in human lung cancer cells [J]. Biomed Pharmacoth, 2018, 108: 809-816. 
[15] Zhong X M, Zhang L, Li Y M, Et Al., Kaempferol alleviates ox - LDL - induced apoptosis by the up - regulation of miR - a - 5 p 26 via inhibiting TLR4 / the nf-kappa B pathway in human endothelial cells [J]. Biomed Pharmacoth, 2018, 108(17): 1783-1789. 
[16] Govindaraju Saravanan, Roshini Arivazhagan, Lee Min-Ho, et al. Conjugated gold nanoclusters enabled efficient for anticancer Ther-apeutics to A549 lung cancer cell [J]. International journal of nanomedi-cine, 2019, 14: 5147-5157. 
[17] Xue Han, Chun-Fang Liu, Na Gao, et al. Kaempferol suppresses proliff-eration but, Macrophages and autophagy by up-regulating microRNA-340 in human lung Cancer cells [J]. Journal of Biomedicine & amp; Pharmacotherapy, 2018, 108: 809-816. 
[18] Wang Shuai, Sun Yu, Li Chunmei, Lu Qun. Research progress of stigmasterol [J]. China Pharmaceutical, 2019, 28(23): 96-98. 
[19] Zughaibi Ta, Suhail M, Tarique M, Et al. Targeting PI3K/Akt/mTOR pathway by different flavonoids: [J]. Int J Mol Sci, 2019, 22 (22): 12455. (In Chinese) 
[20] Sun E J, Wankell M, Palamuthusingam P, et al. Tar⁃ geting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma [J]. Biomedicines, 2021, 9 (11): 1639. 
[21] Yan Jiali, Li Hui. Effect of TP53 and EGFR co-mutation on the prognosis of NSCLC patients after first-line TKI treatment [J]. Inner Mongolia Medical Journal, 2020, 52(1): 23-27. 
[22] Mantovani A, Dinarello C A, Molgora M, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity [J]. Immunity, 2019, 50(4): 778-795. 
[23] ZHOU CB, gastrointestinal cancer and immune responses to intestinal microbial infection [J]. Gastrointestinal Cancer, Gastrointestinal and intestinal microbial Infection chimica et Biophysica Acta Reviews on Cancer, 2019, 1872 (1): 1-10. 
[24] Wang Y, Yin B, Li D, Et al. GSDME mediates caspase-3-de-pendent pyroptosis in gastric cancer [J]. Biochemical and Bio-physical Research Communications, 2018,495 (1): 1418-1425. 
[25] Wang Y, Gao W, Shi X, Et al. Erythrodrugs induce py-roptosis through caspase-3 cleavage of a gasdermin [J]. Nature, 2017,547 (7661): 99-103. 
[26] Jiang Mx, Qi L, Li Ls, Et al. apoptosis in apoptosis induced by apoptosis in vitro [J]. Cell Death Discov, 2020,6 (12): 112-122. 
[27] Yan B, Peng Z, Xing X, et al. Glibenclamide induces apoptosis by activating reactive oxygen species dependent JNK pathway in hepato- cellular Carcinoma cells [J]. Bioscience Reports, 2017; 37 (5): BSR20170685. 
[28] Tan, A C. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC) [J]. Thorac Cancer, 2020, 11 (3): 511-518.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4218
Visits: 166743

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.